Dr Reddy’s shares crash 9% after weak Q1 results. Here’s why these 3 brokerages are bearish
Economic Times 2 hrs ago·23 Jul 2026, 4:15 am
Dr Reddy’s Laboratories saw its stock price drop nearly 9% after the company reported weaker-than-expected first-quarter results for fiscal 2027. The drugmaker's net profit fell by 69% year-on-year to Rs 443 crore, while revenue slipped by 6% to Rs 8,071 crore. This decline was primarily driven by a Rs 240 crore impact related to the semaglutide active pharmaceutical ingredient (API), which includes inventory provisions. Additionally, rising costs for solvents and freight, linked to the ongoing conflict in the Middle East, further compressed the company's earnings margins.
This sharp correction signals that investors are concerned about the company's near-term profitability and its ability to offset these one-time costs. The significant drop in margins and the specific hit from the semaglutide inventory issue have led three major brokerages to adopt a bearish stance on the stock. For investors, the key focus now will be on how quickly management can stabilize margins and whether the company can deliver consistent earnings growth in the coming quarters despite these headwinds.
Key takeaways
- Category: Results.
- AI reads the tone as negative (potentially bearish) for the stock.
- Flagged as a high-impact, market-moving story.
Why it matters
This is a high-impact development and could move the stock. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
